Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Viewed this way, a definition is a decision mechanism. It distinguishes some elements of the universe from the others. Hence ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Amazon Q Developer is a useful AI-powered coding assistant with chat, CLI, Model Context Protocol and agent support, and AWS ...

Skills—a capability that allows users to teach Claude repeatable workflows—was introduced in October, and now Anthropic is ...

As language models (LMs) improve at tasks like image generation, trivia questions, and simple math, you might think that ...

One of the most significant insights from the study is that roboticists must engage both technically and physically with ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...